Prestige Consumer Healthcare (NYSE:PBH) Updates FY 2026 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 4.540-4.540 for the period, compared to the consensus EPS estimate of 4.550. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Prestige Consumer Healthcare Price Performance

PBH traded down $1.45 during midday trading on Thursday, reaching $65.58. 633,258 shares of the company’s stock were exchanged, compared to its average volume of 385,654. The firm has a market capitalization of $3.15 billion, a price-to-earnings ratio of 16.27, a price-to-earnings-growth ratio of 2.02 and a beta of 0.43. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare has a one year low of $57.25 and a one year high of $90.04. The business has a 50-day simple moving average of $62.94 and a two-hundred day simple moving average of $64.12.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The company had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The company’s quarterly revenue was down 2.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, research analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on PBH. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Jefferies Financial Group reduced their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Oppenheimer reduced their target price on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $84.50.

Insiders Place Their Bets

In other news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the transaction, the vice president directly owned 42,329 shares in the company, valued at approximately $2,539,740. The trade was a 1.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cerity Partners LLC raised its stake in Prestige Consumer Healthcare by 5.9% during the 2nd quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after buying an additional 218 shares during the period. Diversify Advisory Services LLC lifted its holdings in shares of Prestige Consumer Healthcare by 4.6% during the 3rd quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock valued at $354,000 after purchasing an additional 256 shares in the last quarter. Geneos Wealth Management Inc. grew its position in shares of Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares during the period. Martingale Asset Management L P increased its stake in Prestige Consumer Healthcare by 0.9% during the 3rd quarter. Martingale Asset Management L P now owns 37,141 shares of the company’s stock worth $2,318,000 after purchasing an additional 339 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its holdings in Prestige Consumer Healthcare by 5.2% during the 3rd quarter. Quadrant Capital Group LLC now owns 7,296 shares of the company’s stock worth $455,000 after buying an additional 360 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).